

Proven lowest infection rates.



The central line you place may be accessed more than **32** times per day in the ICU¹, creating numerous opportunities for pathogens to enter the patient's bloodstream and cause infection.

You aren't the source of the problem, but you can be the solution.

Protect patients from CRBSI after they leave your care with Cook's proven Spectrum technology.



THE RIGHT COMBINATION

Minocycline+rifampin is proven to be the most synergistic combination of antibiotics in reducing infections through two distinct pathways, and has the ability to penetrate the biofilm that forms on all indwelling catheters.



UNMATCHED EVIDENCE

In vitro studies show that our M+R catheters maintain an effective zone of inhibition for up to 21 days—longer than any other catheter.² Over two decades of evidence, including more than 21 peer-reviewed studies and meta-analyses, prove M+R's ability to prevent bloodstream infections.

^{1.} Hatler C, Hebden J, Kaler W, et al. Walk the walk to reduce catheter-related bloodstream infections. *Am Nurse Today*. 2010;5(1):26-30.

^{2.} Hanna H, Bahna P, Reitzel R, et al. Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters. *Antimicrob Agents Chemother.* 2006;50(10):3283-3288.





DECREASED RESISTANCE

More than 10 years of clinical use has shown no evidence that M+R catheters lead to bacterial resistance, and a seven year study of over 500,000 catheter days confirms these results.³ Data indicate that facilities using M+R catheters have a decreased need for systemic antibiotic use.⁴



WORTH SWITCHING

In a challenging clinical environment, a hospital that switches to M+R catheters can expect to see a decrease in CRBSI rates, attributable mortality and CRBSI-related costs. Even high-performing hospitals can switch to Spectrum to drive incremental improvement in CRBSI rates and still achieve substantial reductions in mortality and expenses.



^{3.} Ramos ER, Jiang Y, Hachem R, et al. Is the prolonged use of minocycline/rifampin coated catheters (M/R CVC) associated with increased resistance: a seven year experience in a tertiary cancer center. Poster presented at: SHEA 18th Annual Scientific Meeting; April 5-8, 2008; Orlando, FL.

^{4.} Brooks K, Dauenhauer S, Nelson M. Comparison of an untreated vs. silver/chlorhexidine vs. rifampin/minocycline central venous catheter in reducing catheter-related bloodstream infections. Abstract presented at: APIC 28th Annual Educational Conference and International Meeting; June 10-14, 2001; Seattle, WA.



With lumen flow rates of 6720 and 7380 mL/hour, the 14,100 mL/hour combined flow rate is the industry's highest for an 8 Fr double-lumen central venous catheter.

Lumen Information							Power Injection	
Catheter Fr	Cross-section	Lumen No./ Hub Color	Port	Equivalent gage	Minimum Lumen Volume mL	Approximate Flow Rate mL/hr	Maximum Flow Rate mL/sec	Average Pressure at Maximum Flow psi
7.0 Triple Power Injectable		2	Distal Mid Proximal	16 18 18	0.5 0.3 0.3	4,020 1,500 1,680	10	142.7
8.0 Double Power Injectable		1	Distal Proximal	14 14	0.9 1.0	6,720 7,380	10	54.6
9.0 Triple Power Injectable		1 2 3	Distal Mid Proximal	14 18 18	0.9 0.4 0.4	9,540 1,500 1,620	10	39.0
10.0 Five Lumen Power Injectable		1 2 3 4 5	Distal Mid Mid Proximal Proximal	14 17 17 19	1.0 0.4 0.4 0.2 0.2	8,820 2,880 2,940 840 840	10	32.1

FDA cleared for power injection in 7, 8, 9, 10 Fr power-injectable CVCs only. Power inject contrast media through distal lumen only.



www.cookmedical.com

COOK MEDICAL INCORPORATED

P.O. Box 4195, Bloomington, IN 47402-4195 USA

Phone: 812.339.2235, Toll Free: 800.457.4500, Toll-Free Fax: 800.554.8335

COOK (CANADA) INC.

111 Sandiford Drive, Stouffville, Ontario, L4A 7X5 CANADA Phone: 905.640.7110, Toll Free: 800.668.0300

WILLIAM A. COOK AUSTRALIA PTY. LTD.

95 Brandl Street, Brisbane Technology Park, Eight Mile Plains Brisbane, QLD 4113 AUSTRALIA, Phone: +61 7 3841 1188

WILLIAM COOK EUROPE ApS

Sandet 6, DK-4632, Bjaeverskov, DENMARK, Phone: +45 56 86 86 86

© COOK 2010 CC-BM-SDLMP-EN-201010

AORTIC CRITICAL INTERVENTIONAL LEAD PERIPHERAL WOMEN'S ENDOSCOPY SURGERY UROLOGY INTERVENTION MANAGEMENT INTERVENTION RADIOLOGY HEALTH